Illumina (NASDAQ:ILMN) had its price objective upped by research analysts at Citigroup from $275.00 to $330.00 in a note issued to investors on Monday. The brokerage presently has a “buy” rating on the life sciences company’s stock. Citigroup’s target price would suggest a potential upside of 19.78% from the company’s current price.
A number of other equities analysts have also commented on the company. Morgan Stanley increased their price target on Illumina from $180.00 to $195.00 and gave the company an “underweight” rating in a research note on Thursday, May 31st. Canaccord Genuity increased their price target on Illumina from $270.00 to $290.00 and gave the company a “top pick” rating in a research note on Tuesday, May 29th. Barclays raised Illumina from an “equal weight” rating to an “overweight” rating and set a $235.00 price target for the company in a research note on Monday, May 7th. ValuEngine lowered Illumina from a “buy” rating to a “hold” rating in a research note on Thursday, April 26th. Finally, BTIG Research reissued a “hold” rating on shares of Illumina in a research note on Wednesday, April 25th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, fifteen have given a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $256.42.
Shares of Illumina stock opened at $275.51 on Monday. Illumina has a 12 month low of $167.98 and a 12 month high of $293.15. The company has a market cap of $41.55 billion, a P/E ratio of 68.88, a PEG ratio of 3.02 and a beta of 0.88. The company has a debt-to-equity ratio of 0.23, a current ratio of 2.71 and a quick ratio of 2.41.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, April 24th. The life sciences company reported $1.45 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.43. Illumina had a return on equity of 24.93% and a net margin of 19.31%. The company had revenue of $782.00 million during the quarter, compared to analyst estimates of $744.30 million. During the same period in the prior year, the company earned $0.64 earnings per share. The firm’s revenue was up 30.8% on a year-over-year basis. research analysts predict that Illumina will post 4.86 earnings per share for the current year.
In related news, Director A Blaine Bowman sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, April 2nd. The stock was sold at an average price of $230.13, for a total transaction of $690,390.00. Following the completion of the sale, the director now directly owns 19,868 shares of the company’s stock, valued at approximately $4,572,222.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Mostafa Ronaghi sold 10,500 shares of the firm’s stock in a transaction that occurred on Monday, June 11th. The stock was sold at an average price of $284.83, for a total value of $2,990,715.00. Following the sale, the senior vice president now directly owns 81,496 shares of the company’s stock, valued at $23,212,505.68. The disclosure for this sale can be found here. Insiders sold a total of 39,271 shares of company stock valued at $10,483,503 over the last ninety days. Corporate insiders own 0.54% of the company’s stock.
Hedge funds have recently modified their holdings of the stock. Financial Gravity Companies Inc. bought a new stake in shares of Illumina during the 4th quarter worth approximately $106,000. Harvest Fund Management Co. Ltd bought a new stake in shares of Illumina during the 1st quarter worth approximately $113,000. Captrust Financial Advisors bought a new stake in shares of Illumina during the 4th quarter worth approximately $165,000. Financial Gravity Wealth Inc. bought a new stake in shares of Illumina during the 1st quarter worth approximately $193,000. Finally, Summit Trail Advisors LLC lifted its stake in shares of Illumina by 21,172.1% during the 1st quarter. Summit Trail Advisors LLC now owns 194,852 shares of the life sciences company’s stock worth $195,000 after acquiring an additional 193,936 shares during the last quarter. 90.54% of the stock is owned by hedge funds and other institutional investors.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.